Infektološki glasnik, Vol. 33 No. 1, 2013.
Izvorni znanstveni članak
Efficacy of treatment with peginterferon alfa-2 plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
Ivan Kurelac
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Neven Papić
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Snježana Židovec Lepej
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Davorka Dušek
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Vjeran Čajić
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Adriana Vince
; Klinika za infektivne bolesti "Dr. Fran Mihaljević", Zagreb, Hrvatska
Sažetak
About 55% of patients with genotype 1 chronic hepatitis C infection have sustained response to 48-week therapy with pegylated interferon alfa-2 and ribavirin. Previous studies have shown that patients with low pretreatment viremia (< 600 000 IU/mL) can be treated for 24 weeks with similar efficacy as with 48-week therapy, when early viral kinetic is measured. Our study showed that patients with low pretreatment viral load (< 600 000 IU/mL) are very heterogenous group and sustained viral response to pegylated interferon alfa-2 and ribavirin therapy is not better than in high viral load group (low viremia patients SVR 53.2% (n = 94), high viremia patients SVR 50.8% (n = 122)). Pretreatment low viral load patients that did not achieve SVR (n = 44) had a significantly higher fibrosis stage (non-SVR fibrosis stage 3.47 Ishak score vs. SVR+ fibrosis stage 2.94; p = 0,004), and they were significantly older (non-SVR patients 46.4 years, SVR+ patients 39.6 years, p = 0.008). Low initial viremia patients with cirrhosis (n = 6) did not achieve SVR at all, while among patients with fibrosis stage 4/6, 52 % achieved SVR. Our results suggest that apart from viral load at the beginning of treatment, fibrosis stage is also a predicting factor for therapy outcome, particularly in older patients and patients with cirrhosis.
Ključne riječi
Hepatitis C; peginterferon alfa-2 and ribavirin treatment; low viral load; genotype 1; fibrosis stage; SVR; therapy outcome predictors
Hrčak ID:
106536
URI
Datum izdavanja:
31.3.2013.
Posjeta: 1.512 *